You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR ROPINIROLE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for ropinirole hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00363727 ↗ Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's Completed GlaxoSmithKline Phase 3 2003-12-01 This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.
New Formulation NCT03250117 ↗ Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole Terminated Titan Pharmaceuticals Phase 1/Phase 2 2017-10-10 Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeura™ implant technology where the implant is inserted under the skin. This study will measure how much ropinirole is released in the blood during 3 months of treatment, and evaluate the side effects of this new formulation.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for ropinirole hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036218 ↗ Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease. Completed Pfizer Phase 3 2001-12-01 The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.
NCT00086294 ↗ ACP-103 to Treat Parkinson's Disease Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 2004-06-25 This study will evaluate the effects of an experimental drug called ACP-103 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term levodopa treatment. ACP-103 changes the spread of certain brain signals that are affected in patients with Parkinson's disease. Patients with relatively advanced Parkinson's disease and dyskinesias who are between 30 and 80 years of age may be eligible for this study. Candidates are screened with a complete medical history and physical examination, neurological evaluation, blood and urine tests, and electrocardiogram (ECG). A brain magnetic resonance imaging (MRI) scan, CT scan, and chest x-ray may be done if medically indicated. Patients enrolled in the study will, if possible, stop taking all antiparkinsonian medications for one month (2 months for Selegiline) before the study begins and throughout its duration. Exceptions are Sinemet (levodopa/carbidopa), Mirapex (pramipexole) and Requip (ropinirole). Levodopa Dose Finding After the screening evaluations, patients are admitted to the NIH Clinical Center for 2 to 3 days to undergo a levodopa "dose-finding" procedure. For this test, patients stop taking Sinemet and instead have levodopa infused through a vein. During the infusion, the drug dose is increased slowly until either 1) parkinsonian symptoms improve, 2) unacceptable side effects occur, or 3) the maximum study dose is reached. Side effects are monitored closely during the infusions, and parkinsonian symptoms are evaluated frequently during and after the infusions. The infusions usually begin early in the morning and continue until evening. Once the infusion is finished, patients resume taking their regular oral Sinemet dose. The infusions are repeated once a week during 1-day inpatient evaluations. Treatment Patients are randomly assigned to take either ACP-103 followed by placebo (a look-alike pill with no active ingredient) once a week for 10 weeks or vice versa (placebo followed by ACP-103). Patients are admitted to the Clinical Center for each dose. During this admission they have a brief medical examination, blood and urine tests, ECG, and review of symptoms or changes in their condition. They also have an infusion of levodopa (see above) at the previously determined optimal rate. Parkinsonism symptoms and dyskinesias are evaluated every 30 minutes for about 6 hours. At the end of the infusions and ratings, patients are discharged home with their regular Parkinson's medications until the following visit. Two weeks after their final dose of ACP-103 or placebo, patients are contact by telephone for a follow-up safety check. At that time, the investigator may ask the patient to return to the clinic for closer evaluation.
NCT00140712 ↗ Ropinirole Tablets In Young Patients With Restless Legs Syndrome Completed GlaxoSmithKline Phase 1 2005-06-10 This is a two-period dose rising study of Ropinirole Immediate Release in adolescent patients with restless legs syndrome (RLS) in order to determine the starting dose for the ropinirole titration regimen for this age group. Patients will receive two single doses unless poor tolerability is observed following the first dose.
NCT00144300 ↗ Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients Completed Boehringer Ingelheim Phase 4 2005-01-01 To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.
NCT00197080 ↗ Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome Completed GlaxoSmithKline Phase 3 2005-06-01 The purpose of this study is to assess the efficacy and safety of ropinirole XR in the treatment of adults with Restless Legs Syndrome (RLS).
NCT00200941 ↗ Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome Completed Ortho-McNeil Pharmaceutical Phase 4 2001-08-01 This study is intended to determine whether topiramate is an efficacious and safe treatment for restless legs syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ropinirole hydrochloride

Condition Name

Condition Name for ropinirole hydrochloride
Intervention Trials
Restless Legs Syndrome 21
Parkinson Disease 21
Parkinson's Disease 14
Restless Legs Syndrome (RLS) 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ropinirole hydrochloride
Intervention Trials
Parkinson Disease 34
Restless Legs Syndrome 23
Psychomotor Agitation 20
Syndrome 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ropinirole hydrochloride

Trials by Country

Trials by Country for ropinirole hydrochloride
Location Trials
United States 313
Germany 47
Italy 26
United Kingdom 19
Canada 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ropinirole hydrochloride
Location Trials
Florida 17
California 17
Georgia 16
New York 15
Texas 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ropinirole hydrochloride

Clinical Trial Phase

Clinical Trial Phase for ropinirole hydrochloride
Clinical Trial Phase Trials
Phase 4 15
Phase 3 28
Phase 2 11
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ropinirole hydrochloride
Clinical Trial Phase Trials
Completed 62
Terminated 4
Unknown status 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ropinirole hydrochloride

Sponsor Name

Sponsor Name for ropinirole hydrochloride
Sponsor Trials
GlaxoSmithKline 38
UCB Pharma 4
Otsuka Pharmaceutical Co., Ltd. 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ropinirole hydrochloride
Sponsor Trials
Industry 63
Other 25
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.